China has administered more than one billion doses of its homegrown COVID-19 vaccines, the majority of which were developed by local companies Sinovac and Sinopharm. So what do we know about them?
Academic rigour, journalistic flair
Articles on Sinovac
Displaying all articles
With richer countries having bought up most of the leading western vaccines, others are looking to India, China and Russia for supplies.
A primer on Sinovac, Sinopharm and CanSino, and their prospects for achieving a world first for coronavirus.
Top contributors
-
Senior Lecturer, Global Development Institute, University of Manchester
-
Professor of Innovation and Strategy, International Institute for Management Development (IMD)
-
Senior Principal Research Fellow; paediatrician; infectious diseases epidemiologist; vaccinologist, The University of Melbourne
-
Clinical researcher, Murdoch Children's Research Institute
